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Abstract  
AIM: The main goal of the present study was to find azole-resistant and molecular analysis of cyp51A gene in 
Aspergillus fumigatus.  
MATERIALS AND METHODS: Fifty-eight A. fumigatus strains including environmental, clinical and reference 
isolates were assessed in this investigation. Azole susceptibility testing for itraconazole and voriconazole was 
carried out for A. fumigatus isolates. PCR was performed based on cyp51A gene sequence for all isolates.  
RESULTS: Susceptibility testing verified the minimum inhibitory concentrations (MICs) for itraconazole (0.125 to 2 
µg/ml) and voriconazole (0.125 to 4 µg/ml). Nine (15.5%) A. fumigatus isolates were resistant to voriconazole with 
MIC 4 µg/ml. A 1500 bp DNA fragment was amplified using cyp51A gene for all tested Aspergillus isolates. The 
sequences of the fragments showed 99% identity with A. fumigatus cyp51A gene in the GenBank. No point 
mutation was found at cyp51A gene codons. 
CONCLUSION: In the current study, we detected the voriconazile resistant in A. fumigatus isolates. Susceptibility 
tests should be considered in patients who infected by A. fumigatus. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Aspergillus fumigatus is one of the most 
common airborne fungal pathogen which causes 
invasive aspergillosis. The spores are capable of 
spreading to air and inhaled and eventually cause 
infection in a susceptible host. A. fumigatus infections 
occur in excessive morbidity and mortality in 
immunocompromised hosts [1] [2]. The azoles are 
antifungal drugs that inhibit the ergosterol 
biosynthesis pathway by the inhibition of 14α-
demethylase. Azoles, for example, itraconazole, 
voriconazole, and posaconazole are among the 
advised first-line agents in the management and 
prophylaxis of aspergillosis [3]. 
The appearance of azoles resistance in yeast 
species has encouraged researchers of the 
mechanisms associated with this resistance. Several 
genes encoding 14α-demethylase (ERG11/cyp51) 
have been identified for fluconazole-resistant of the 
clinical isolates of Candida albicans [4] [5]. 
The mechanisms for azole drug resistance in 
A. fumigatus appear to be extremely dissimilar from 
that in Candida spp. There are two various but related 
Cyp51 proteins which are encoded by cyp51A and 
cyp51B genes [6] [7].  
Two models of resistance to azoles have 
discovered in A. fumigatus. First, the A. fumigatus 
could turn into resistant during exposure to azoles in 
the patient. This model was detected in chronic 
pulmonary aspergillosis and aspergilloma cases in the 
United Kingdom [8]. In this pattern, eighteen dissimilar 
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amino acid substitutions were distinguished in the 
cyp51A gene [8]. Second, the A. fumigatus can turn 
into resistance in the environment during the exposure 
to azole fungicides which are applied in agriculture 
and material conservation. 
This model was suggested in the Netherlands 
[9]. In this pattern, a replacement at codon 98 of the 
cyp51A gene combined with a tandem repeat of 34 bp 
in the promoter (TR/L98H), was detected in 94% of 
the resistant strains [10]. 
Treatment of invasive aspergillosis is mainly 
limited to therapy by the polyene agent amphotericin 
B, and triazoles such as itraconazole, voriconazole 
and echinocandin caspofungin. Amphotericin B is very 
toxic and can consequence in nephrotoxicity [11], 
while triazoles are fungistatic and subject to 
development of resistance [12]. 
Here, we explain the analysis of cyp51A gene 
A. fumigatus which is responsible for the phenotype of 
A. fumigatus azole-resistance. 
 
 
Material and Methods 
 
A total of 58 A. fumigatus strains were used in 
the study including 45 environmental, 9 clinical and 4 
reference isolates. The following strains were used as 
a reference: PTCC 5009, IBRC-M 30033, IBRC-M 
30040, IBRC-M 30048. Environmental strains were 
recovered from soil or air. 
One hundred ml of yeast extract peptone 
dextrose (YEPD) medium in Erlenmeyer flasks was 
inoculated with 1 ml of thick spore suspension and 
incubated at 37°C for 72 h 200 rpm under agitation to 
obtain mycelium growth. The mycelia were harvested, 
washed with 0.5 M EDTA and sterile dH2O and using 
liquid nitrogen and a pestle and mortar ground into a 
fine powder. The DNA was extracted with vivantis is 
GF-1 plant DNA extraction kit, Malaysia.  
The primer sets, P450-A1 (5'-
ATGGTGCCGATGCTATGG-3') and P450-A2 (5'-
CTGTC-TCACTTGGATGTG-3') was used to amplify 
an ~ 1500 bp DNA fragment of the full coding 
sequences of cyp51A gene. PCR reactions were 
carried out with a volume of 30 μl, comprised of 3 μl 
10X reaction buffer, 200 μM each dNTP, 2.2 mM 
MgCl2, 2.5 units of Taq DNA polymerase (CinnaGen, 
Tehran, Iran), 30 ng template DNA and 50 pmol of 
each primer. 
Initial denaturation for 5 min at 94°C was 
followed by 30 cycles of denaturation at 94°C for 1 
min, annealing at 58˚C for 1 min and extension at 
68˚C for 2 min. The PCR product (5 μl) was 
electrophoresed on 1% agarose gel in TAE buffer and 
stained with ethidium bromide.  
Spore suspension for each isolate was set up 
in sterile normal saline and adjusted at a 
concentration of 10
6 
spores/ml, consequent to 68 to 
82% transmittance at 530 nm [13]. Broth microdilution 
susceptibility test was carried out as explained in 
clinical and laboratory standards institute (CLSI) 
method with modifications. The antifungal drugs used 
were itraconazole (Sigma-Aldrich, Germany) and 
voriconazole (Sigma-Aldrich, Germany). 
Stock solutions were prepared in 100% 
dimethyl sulfoxide (CinnaGene, Karaj, Iran), then 
diluted in RPMI 1640 medium and dispensed into 96-
well microdilution trays. The final concentration of 
voriconazole and itraconazole in the wells ranged 
from 0.015 to 8.0 µg/ml. The stock spore suspension 
(10
6
 spores/ml) was diluted to a final concentration of 
5 × 10
4
 CFU/ml and dispensed into the microdilution 
wells. The inoculated microdilution trays were kept at 
35°C and read after 48 h. The minimum inhibitory 
concentration (MIC) for voriconazole and itraconazole 
was described as the lowest concentration that 
created prominent growth inhibition. 
Some cyp51A gene amplicons were 
submitted for direct sequencing (Bioneer Corporation, 
Daejeon, South Korea). The obtained sequences 
were searched for in the National Center for 
Biotechnology Information (NCBI) database 
(http://www.ncbi.nih.gov/). 
The sequences showed 99% similarity with A. 
fumigatus cyp51A gene sequences deposited in NCBI 
database. The computer software package MEGA5 
(http://www.megasoftware.net) was employed for 
sequences alignment. 
 
 
Results 
 
A total of 58 samples were tested including 45 
environmental, 9 clinical and 4 reference isolates, 
according to the European committee for antibiotic 
susceptibility testing (Eucast) methodology suggestion 
breakpoints for A. fumigatus, itraconazole and 
voriconazole [14]. For itraconazole and voriconazole, 
<2 µg/ml (susceptible), 2 µg/ml (intermediate) and >2 
µg/ml (resistant). Susceptibility testing verified the 
MICs for itraconazole (0.125 to 2 µg/ml) and 
voriconazole (0.125 to 4 µg/ml) (Table 1).  
Nine (15.5%) A. fumigatus isolates were 
resistant to voriconazole with MIC 4 µg/ml. Twelve 
(20.7%) isolates exhibited intermediate susceptibility 
to itraconazole with MIC 2 µg/ml. The PCR 
amplification of cyp51A gene with set primers P450-
A1 and P450-A2 produced a 1500 bp fragment for all 
tested Aspergillus isolates (Fig. 1).  
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Table 1: Results of susceptibility testing voriconazole and 
itraconazole for A. fumigatus isolates 
Isolate number Source MIC (µg/ml) for 
voriconazole 
MIC (µg/ml) for 
itraconazole 
3/M Environmental 2 1 
4/M Environmental 2 0.5 
5/M Environmental 2 1 
6/M Environmental 0.5 0.5 
8/M Environmental 2 1 
11/M Environmental 1 1 
12/M Environmental 1 2 
13/M Environmental 4 0.5 
14/M Environmental 0.5 1 
15/M Environmental 0.5 2 
16/M Environmental 2 2 
17/M Environmental 4 0.5 
19/M Environmental 2 0.5 
20/M Environmental 1 1 
21/M Environmental 2 1 
22/M Environmental 2 1 
23/M Environmental 0.125 0.5 
24/M Environmental 4 0.5 
26/M Environmental 2 1 
27/M Environmental 0.5 2 
28/M Environmental 2 1 
29/M Environmental 1 1 
30/M Environmental 1 2 
31/M Environmental 2 1 
32/M Environmental 1 1 
34/M Environmental 2 2 
36/M Environmental 2 1 
37/M Environmental 4 0.5 
38/M Environmental 2 1 
44/M Environmental 2 0.5 
45/M Environmental 4 0.5 
46/M Environmental 2 1 
6/1 Environmental 2 1 
6/2 Environmental 2 2 
6/3 Environmental 4 2 
7/1 Environmental 2 1 
7/2 Environmental 2 0.5 
7/3 Environmental 2 0.5 
7/4 Environmental 2 0.5 
7/5 Environmental 4 0.5 
7/6 Environmental 2 1 
9/1 Environmental 2 0.5 
10/1 Environmental 2 2 
11/1 Environmental 2 1 
18/1 Environmental 2 0.5 
1/B Clinical 2 1 
2/B Clinical 2 0.5 
3/B Clinical 2 1 
4/B Clinical 2 0.5 
70/B Clinical 1 2 
72/B Clinical 1 1 
98j/B Clinical 1 1 
1010/B Clinical 0.25 2 
MEH Clinical 0.5 2 
PTCC 5009 Reference 1 0.125 
IBRC-M 30033 Reference 2 0.5 
IBRC-M 30040 Reference 4 0.5 
IBRC-M 30048 Reference 4 0.5 
 
Several cyp51A gene amplicons including 
nine voriconazole resistant isolates were sent for 
direct sequencing. The sequences were searched in 
the NCBI database.  
 
Figure 1: Agarose gel electrophoresis of cyp51A gene products 
(1500 bp) of Aspergillus fumigatus isolates (lanes 1, 2, reference 
strains; lanes 3-7, clinical isolates; lanes 8-12, environmental 
isolates). Lane M, 1 kb ladder; lane 1, 30040; lane 2, 30048; lane 3, 
2/B; lane 4, 4/B; lane 5, 72/B; lane 6, 1010/B; lane 7, Meh; lane 8, 
7/4, lane 9, 10/1; lane 10, 18/1; lane 11, 19/M; lane 12, 22/M 
 
The sequences showed 99% identity with A. 
fumigatus sequences deposited in the NCBI 
database. The computer software MEGA5 was 
applied for sequences alignment. Although nine 
isolates were found to be resistant to voriconazole, we 
did not find any isolate with a point mutation in their 
cyp51A gene codons. 
 
 
Discussion 
 
Rapid recognition of Aspergillus infections 
with a precise assessment of possible drug resistance 
is vital for successful management of patients with 
invasive infection. Clinically, triazole resistance rates 
are different between 2 and 6.6% among samples [15] 
[16]. In 1997 the first case of A. fumigatus 
itraconazole resistant was reported [17]. Research 
from the Netherlands reported that 3 of 114 A. 
fumigatus isolates were resistant to itraconazole 
although all had MICs for all of them were low for 
voriconazole [18]. 
Some researchers reported that a point 
mutation that substituted the glycine at codon 54 of 
CYP51A was created itraconazole resistant in A. 
fumigatus [19][20]. Mechanisms of resistance to azole 
have been explained in other fungi, particularly C. 
albicans. Triazoles are the foundation of therapy with 
voriconazole the first-choice treatment for invasive 
aspergillosis [21]. Nevertheless, azole resistance 
reports have appeared, not only after long time azole 
usage [8] but also after a short time using and in 
azole-naive cases [10]. 
Resistance to azole in A. fumigatus has been 
connected with mutations in cyp51A gene that is a 
target for antifungal azoles. The occurrence of cyp51A 
mutations has been related to a failure in treatment. 
Management of invasive aspergillosis is 
complicated because of negative cultures is frequent, 
and many laboratories do not carry out susceptibility 
assessments on isolates of Aspergillus. Therefore, the 
frequency of azole-resistant to Aspergillus likely 
underdiagnosed, with a possible risk of unsuitable 
treatment. 
In our study MICs for itraconazole between 
0.125 to 2 mg/ litre and voriconazole between 0.125 to 
4 mg/ litre were obtained. Nine of the isolates 
including 7 environmental isolates and 2 standard 
isolates were resistant to voriconazole with MIC 4mg/ 
litre. None of the resistance strains showed point 
mutation in cyp51A gene.  
We consider that the results of our 
investigation and the rising reports on azole-
resistance propose that susceptibility examinations of 
A. fumigatus isolates must be regularly carried out. 
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